Emerging drugs to treat juvenile idiopathic arthritis

Expert Opinion on Emerging Drugs

Volumn 16, Issue 3, 2011, Pages 493-505

  Ruperto, Nicolino ^a   Martini, Alberto ^a,b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

biological agents; joint damage; juvenile idiopathic arthritis; small molecules

Indexed keywords

ABATACEPT; ADALIMUMAB; ARKALIST; CANAKINUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACET; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG;

BIOLOGICAL THERAPY; DISEASE CLASSIFICATION; DRUG LEGISLATION; DRUG RESEARCH; DRUG TARGETING; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; OUTCOMES RESEARCH; REVIEW; VALIDATION STUDY;

ADOLESCENT; ANIMALS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80051975943     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.581662     Document Type: Review

References (116)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78 A clinical review on juvenile idiopathic arthritis.
2. Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis: New perspectives on classification, pathogenesis and treatment. Lancet 2011;in press A clinical and pathogenetic review on juvenile idiopathic arthritis.
3. Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritides: Durban, 1997. J Rheumatol 1998;25:1991-4
4. Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: Second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2
5. Martini A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J Rheumatol 2003;30:1900-3
6. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease? J Rheumatol 1998;25:203-7
7. De Benedetti F, Martini A. Targeting the interleukin-6 receptor: A new treatment for systemic juvenile idiopathic arthritis? Arthritis Rheum 2005;52:687-93
8. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal Phase III trial. Lancet 2008;371:998-1006 Phase III trial with tocilizuman in juvenile idiopathic arthritis.
9. De Benedetti F, Brunner HI, Ruperto N, et al. Efficacy and safety of tocilizumab in patients with systemic juvenile idiopathic arthritis (sJIA): 12-week data from the Phase III TENDER Trial. Ann Rheum Dis 2010;69
10. Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005;201:1479-86 Role of IL-1 in systemic juvenile idiopathic arthritis.
11. Gattorno M, Sormani MP, D'Osualdo A, et al. A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children. Arthritis Rheum 2008;58:1823-32
12. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581-92
13. Gattorno M, Tassi S, Carta S, et al. Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. Arthritis Rheum 2007;56:3138-48 Role of IL-1 in systemic juvenile idiopathic arthritis.
14. Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 2011;70:747-54
15. Nigrovic PA, Mannion M, Prince FH, et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: Report of forty-six patients from an international multicenter series. Arthritis Rheum 2011;63:545-55
16. Susic GZ, Stojanovic RM, Pejnovic NN, et al. Analysis of disease activity, functional disability and articular damage in patients with juvenile idiopathic arthritis: A prospective outcome study. Clin Exp Rheumatol 2011; published online, doi:3987 [pii]
17. Ringold S, Seidel KD, Koepsell TD, Wallace CA. Inactive disease in polyarticular juvenile idiopathic arthritis: Current patterns and associations. Rheumatology (Oxford) 2009;48:972-7
18. Ravelli A, Felici E, Magni-Manzoni S, et al. Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease. Arthritis Rheum 2005;52:826-32
19. Ravelli A, Varnier GC, Oliveira S, et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum 2011;63:267-75
20. Magni-Manzoni S, Pistorio A, Labo E, et al. A longitudinal analysis of physical functional disability over the course of juvenile idiopathic arthritis. Ann Rheum Dis 2008;67:1159-64
21. Ravelli A, Manzoni SM, Viola S, et al. Factors affecting the efficacy of intraarticular corticosteroid injection of knees in juvenile idiopathic arthritis. J Rheumatol 2001;28:2100-2
22. Solari N, Viola S, Pistorio A, et al. Assessing current outcomes of juvenile idiopathic arthritis: A cross-sectional study in a tertiary center sample. Arthritis Rheum 2008;59:1571-9
23. Griffin TA, Barnes MG, Ilowite NT, et al. Gene expression signatures in polyarticular juvenile idiopathic arthritis demonstrate disease heterogeneity and offer a molecular classification of disease subsets. Arthritis Rheum 2009;60:2113-23
24. Barnes MG, Grom AA, Thompson SD, et al. Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum 2010;62:3249-58
25. Bartoli M, Taro M, Magni-Manzoni S, et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2008;67:370-4
26. Stoll ML, Lio P, Sundel RP, Nigrovic PA. Comparison of Vancouver and International League of Associations for rheumatology classification criteria for juvenile psoriatic arthritis. Arthritis Rheum 2008;59:51-8
27. Stoll ML, Zurakowski D, Nigrovic LE, et al. Patients with juvenile psoriatic arthritis comprise two distinct populations. Arthritis Rheum 2006;54:3564-72
28. Connor JD. A look at the future of pediatric therapeutics: An investigator's perspective of the new pediatric rule. Pediatrics 1999;104:610-13
29. Ruperto N, Martini A, for the Paediatric Rheumatology International Trials Organization (PRINTO). Use of unlabelled and off licence drugs in children. A European paediatric rule is needed to protect children. BMJ 2000;320:1210-11
30. Ruperto N, Martini A, for the Paediatric Rheumatology International Trials Organisation (PRINTO). Networking in pediatrics: The example of the Pediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child 2011;epub ahed of print The role of networking in pediatric rheumatology.
31. Ruperto N, Martini A. International research networks in pediatric rheumatology: The PRINTO perspective. Curr Opin Rheumatol 2004;16:566-70
32. Ruperto N, Giannini EH, Pistorio A, et al. Is it time to move to active comparator trials in juvenile idiopathic arthritis? A review of current study designs. Arthritis Rheum 2010;62:3131-9 Current study designs in juvenile idiopathic arthritis.
33. Giannini EH, Lovell DJ, Silverman ED, et al. Intravenous immunoglobulin in the treatment of polyarticular juvenile rheumatoid arthritis: A Phase I/II study. J Rheumatol 1996;23:919-24
34. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9 Criteria to evaluate response to therapy in juvenile idiopathic arthritis.
35. Damasio MB, Malattia C, Martini A, Toma P. Synovial and inflammatory diseases in childhood: Role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatr Radiol 2010;40:985-98
36. Babyn P, Doria AS. Radiologic investigation of rheumatic diseases. Rheum Dis Clin North Am 2007;33:403-40
37. Ravelli A, Ioseliani M, Norambuena X, et al. Adapted versions of the Sharp/van der Heijde score are reliable and valid for assessment of radiographic progression in juvenile idiopathic arthritis. Arthritis Rheum 2007;56:3087-95
38. Malattia C, Damasio MB, Magnaguagno F, et al. Magnetic resonance imaging, ultrasonography, and conventional radiography in the assessment of bone erosions in juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1764-72
39. Malattia C, Damasio MB, Pistorio A, et al. Development and preliminary validation of a paediatric-targeted MRI scoring system for the assessment of disease activity and damage in juvenile idiopathic arthritis. Ann Rheum Dis 2010; published online, doi: Ard.2009.126862 [pii];10.1136/ ard.2009.126862 [doi]
40. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USAUSSR. double-blind, placebo-controlled trial. N Engl J Med 1992;326:1043-9 Phase III trial with methotrexate in juvenile idiopathic arthritis.
41. Ruperto N, Murray KJ, Gerloni V, et al. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004;50:2191-201 Phase III trial with higher methotrexate doses in juvenile idiopathic arthritis.
42. Silverman E, Mouy R, Spiegel L, et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655-66 Phase III trial with leflunomide in juvenile idiopathic arthritis.
43. Van Rossum MA, Fiselier TJ, Franssen MJ, et al. Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study. Dutch Juvenile Chronic Arthritis Study Group. Arthritis Rheum 1998;41:808-16 Phase III trial with sulfasalazine in juvenile idiopathic arthritis.
44. Beukelman T, Patkar NM, Saag KG, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63:465-82 American College of Rheumatology recommendation for the treatment of JIA.
45. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763-9 Phase III trial with etanercept in juvenile idiopathic arthritis.
46. Horneff G, Schmeling H, Biedermann T, et al. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638-44 Phase IV study with etanercept in juvenile idiopathic arthritis.
47. Prince FH, Twilt M, Ten CR, et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: The Dutch national register. Ann Rheum Dis 2009;68:635-41
48. Giannini EH, Ilowite NT, Lovell DJ, et al. Effects of long-term etanercept treatment on growth in children with selected categories of juvenile idiopathic arthritis. Arthritis Rheum 2010;62:3259-64
49. Ruperto N, Lovell DJ, Cuttica R, et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096-106 Phase III trial with infliximab in juvenile idiopathic arthritis.
50. Ruperto N, Lovell DJ, Cuttica R, et al. Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: Findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718-22
51. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810-20 Phase III trial with adalimumab in juvenile idiopathic arthritis.
52. Horneff G, De BF, Foeldvari I, et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): Preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519-25
53. Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26:688-92
54. Hashkes PJ, Uziel Y, Laxer RM. The safety profile of biologic therapies for juvenile idiopathic arthritis. Nat Rev Rheumatol 2010; published online, doi: Nrrheum.2010.142 [pii];10.1038/ nrrheum.2010.142 [doi]
55. Diak P, Siegel J, La GL, et al. Tumor necrosis factor alpha blockers and malignancy in children: Forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62:2517-24
56. Simard J, Neovius M, Hagelberg S, Askling J. Juvenile idiopathic arthritis and risk of cancer: A nationwide cohort study. Arthritis Rheum 2010; published online, doi:10.1002/art. 27741 [doi] Risk of cancer in juvenile idiopathic arthritis.
57. Ruperto N, Martini A. Pediatric rheumatology: JIA, treatment and possible risk of malignancies. Nat Rev Rheumatol 2011;7:6-7
58. Horneff G, Foeldvari I, Minden K, et al. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford) 2011;50:230-6 Risk of cancer in juvenile idiopathic arthritis.
59. Bernatsky S, Rosenberg AM, Oen KG, et al. Malignancies in juvenile idiopathic arthritis: A preliminary report. J Rheumatol 2011;38:760-3 Risk of cancer in juvenile idiopathic arthritis.
60. Ruperto N, Lovell DJ, Quartier P, et al. Abatacept in children with juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383-91 Phase III trial with abatacept in juvenile idiopathic arthritis.
61. Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res 2010;62:1542-51
62. Ruperto N, Lovell DJ, Quartier P, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010; published online, doi:10.1002/ art.27431 [doi]
63. Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: Treatment of juvenile idiopathic arthritis. Arthritis Res 2009;11:216-27
64. Simonini G, Cantarini L, Bresci C, et al. Current therapeutic approaches to autoimmune chronic uveitis in children. Autoimmun Rev 2010;9:674-83
65. Magni-Manzoni S, Ruperto N, Pistorio A, et al. Development and validation of a preliminary definition of minimal disease activity in patients with juvenile idiopathic arthritis. Arthritis Rheum 2008;59:1120-7
66. Wallace CA, Ruperto N, Giannini E, et al. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290-4
67. Ravelli A, Martini A. Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 2006;24:S105-10
68. Lurati A, Salmaso A, Gerloni V, et al. Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: A cohort study of 761 consecutive cases. J Rheumatol 2009;36:1532-5
69. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: A randomized clinical trial. JAMA 2010;303:1266-73 Phase III trial for methotrexate discontinuation in juvenile idiopathic arthritis in remission.
70. Sarkar S, Fox DA. Targeting IL-17 and Th17 cells in rheumatoid arthritis. Rheum Dis Clin North Am 2010;36:345-66
71. Van den Berg WB, Miossec P. IL-17 as a future therapeutic target for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:549-53
72. Annunziato F, Romagnani S. The transient nature of the Th17 phenotype. Eur J Immunol 2010;40:3312-16
73. Agarwal S, Misra R, Aggarwal A. Interleukin 17 levels are increased in juvenile idiopathic arthritis synovial fluid and induce synovial fibroblasts to produce proinflammatory cytokines and matrix metalloproteinases. J Rheumatol 2008;35:515-19
74. Olivito B, Simonini G, Ciullini S, et al. Th17 transcription factor RORC2 is inversely correlated with FOXP3 expression in the joints of children with juvenile idiopathic arthritis. J Rheumatol 2009;36:2017-24
75. Nistala K, Moncrieffe H, Newton KR, et al. Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers. Arthritis Rheum 2008;58:875-87
76. Nistala K, Adams S, Cambrook H, et al. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. Proc Natl Acad Sci USA 2010;107:14751-6
77. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A Phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010;62:929-39
78. Durez P, Chindalore V, Bittmer B. AIN457, an anti-IL17 antibody, shows goodsafety and induces clinical responses in patients with active rheumatoid arthritis (RA) despite methotrexate therapy in a randomized, double-blind proof-of-concept trial. Ann Rheum Dis 2009;68:125
79. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008;452:773-6
80. Puel A, Doffinger R, Natividad A, et al. Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. J Exp Med 2010;207:291-7
81. Steinman L. Mixed results with modulation of TH-17 cells in human autoimmune diseases. Nat Immunol 2010;11:41-4
82. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633-40
83. Krausz S, Boumans MJH, Gerlag DM. A Phase IIa, randomized, placebo-controlled clinical study of Apilimod Mesylate, an oral IL-12/IL-23 inhibitor, in patients with active rheumatoid arthritis. Arthritis Rheum 2010;10(S):S458
84. Sands BE, Jacobson EW, Sylwestrowicz T, et al. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease. Inflamm Bowel Dis 2010;16:1209-18
85. Cohen SB. Targeting the B cell in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010;24:553-63
86. van AS, Agmon-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011;70:414-22
87. Bingham CO III, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. Arthritis Rheum 2010;62:64-74
88. van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum 2010;62:75-81
89. Looney RJ, Srinivasan R, Calabrese LH. The effects of rituximab on immunocompetency in patients with autoimmune disease. Arthritis Rheum 2008;58:5-14
90. Bader-Meunier B. Rituximab treatment in children: Comment on the review by Looney, et al. Arthritis Rheum 2008;58:2583-4
91. Quartier P, Brethon B, Philippet P, et al. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-13
92. Kasher-Meron M, Uziel Y, Amital H. Successful treatment with B-cell depleting therapy for refractory systemic onset juvenile idiopathic arthritis: A case report. Rheumatology (Oxford) 2009;48:445-6
93. Narvaez J, Diaz-Torne C, Juanola X, et al. Rituximab therapy for refractory systemic-onset juvenile idiopathic arthritis. Ann Rheum Dis 2009;68:607-8
94. Feito JG, Pereda CA. Rituximab therapy produced rapid and sustained clinical improvement in a patient with systemic onset juvenile idiopathic arthritis refractory to TNF alpha antagonists. J Clin Rheumatol 2009;15:363-5
95. Ahmadi-Simab K, Lamprecht P, Jankowiak C, Gross WL. Successful treatment of refractory adult onset still's disease with rituximab. Ann Rheum Dis 2006;65:1117-18
96. Ogilvie EM, Khan A, Hubank M, et al. Specific gene expression profiles in systemic juvenile idiopathic arthritis. Arthritis Rheum 2007;56:1954-65
97. Kuek A, Hazleman BL, Gaston JH, Ostor AJ. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. Rheumatology (Oxford) 2006;45:1448-9
98. Corcione A, Ferlito F, Gattorno M, et al. Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis. Arthritis Res Ther 2009;11:R150
99. Gregorio A, Gambini C, Gerloni V, et al. Lymphoid neogenesis in juvenile idiopathic arthritis correlates with ANA positivity and plasma cells infiltration. Rheumatology (Oxford) 2007;46:308-13
100. Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev 2008;223:132-42
101. Riese RJ, Krishnaswami S, Kremer J. Inhibition of JAK kinases in patients with rheumatoid arthritis: Scientific rationale and clinical outcomes. Best Pract Res Clin Rheumatol 2010;24:513-26
102. Connel CA, Riese R, Wood S. Tasocitinib (CP-690,550), an orally available Janus kinase inhibitor, exhibits sustained safety and efficacy in the treatment of rheumatoid arthritis over 24 months. Arthritis Rheum 2010;10(S):S473
103. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905
104. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:3309-18
105. Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12
106. Genovese MC, Kavanaugh A, Weinblatt ME, et al. An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents. Arthritis Rheum 2010; published online, doi:10.1002/art.30114 [doi]
107. Schett G. Erosive arthritis. Arthritis Res Ther 2007;9(Suppl 1):S2
108. Masi L, Simonini G, Piscitelli E, et al. Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: Is there a potential modulating role for OPG/ RANK-L in bone injury? J Rheumatol 2004;31:986-91
109. Varsani H, Patel A, van KY, et al. Synovial dendritic cells in juvenile idiopathic arthritis (JIA) express receptor activator of NF-kappaB (RANK). Rheumatology (Oxford) 2003;42:583-90
110. Spelling P, Bonfa E, Caparbo VF, Pereira RM. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: A bone damage biomarker? Scand J Rheumatol 2008;37:439-44
111. Sarma PK, Misra R, Aggarwal A. Elevated serum receptor activator of NFkappaB ligand (RANKL), osteoprotegerin (OPG), matrix metalloproteinase (MMP)3, and ProMMP1 in patients with juvenile idiopathic arthritis. Clin Rheumatol 2008;27:289-94
112. Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010;69:872-5
113. Deodhar A, Dore RK, Mandel D, et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2010;62:569-74
114. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-309
115. Sharp JT, Tsuji W, Ory P, et al. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:537-44
116. Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007;39:960-2